|Company name||ACADIA Pharmaceuticals Inc.|
NEW YORK, July 9, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against ACADIA Pharmaceuticals Inc. (NYSE: ACAD). Our investigation concerns whether ACADIA violated the federal securities laws and/or engaged in other unlawful business practices.
On April 9, 2018, CNN reported that Nuplazid, Acadia’s Parkinson’s disease psychosis treatment, has been associated with more than 700 deaths, and that adverse event reports concerning the drug link it to additional life-threatening incidents, falls, insomnia, nausea, and fatigue. On this news, Acadia’s share price fell $5.03, or 23.36%, to close at $16.50 on April 9, 2018.
On July 9, 2018, a report was published by The Southern Investigative Reporting Foundation alleging that ACADIA’s “pursuit of regulatory approval is best described as ‘loophole-centric’.”
If you purchased or otherwise acquired ACADIA shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.